Soleno Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1999-08-25
- Employees
- 42
- Market Cap
- $1.9B
- Website
- http://www.soleno.life
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Phase 3
Active, not recruiting
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: DCCR
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05701774
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇬🇧The Queen Elizabeth University, Glasgow, United Kingdom
🇺🇸Children's Hospital and Clinic Minnesota, Saint Paul, Minnesota, United States
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
Phase 2
Not yet recruiting
- Conditions
- SH2B1 Deficiency ObesityObesity Associated With PCSK1 Mutation (rs6232 Variant)SIM1 Deficiency Obesity
- Interventions
- Drug: DCCR (diazoxide choline) extended-release tablets
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05532020
PWS Outcomes Assessment Study
Completed
- Conditions
- Prader-Willi Syndrome
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT04102839
- Locations
- 🇺🇸
Casimir Trials, Plymouth, Massachusetts, United States
An Open-Label Study of DCCR Tablet in Patients With PWS
Phase 3
Withdrawn
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: DCCR
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Registration Number
- NCT04086810
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Phase 3
Completed
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: DCCRDrug: Placebo for DCCR
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT03714373
- Locations
- 🇺🇸
Research Institute of Dallas, Dallas, Texas, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
Phase 3
Completed
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: Placebo for DCCRDrug: DCCR
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT03440814
- Locations
- 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸Research Institute of Dallas, Dallas, Texas, United States
🇺🇸Children's Minnesota, Saint Paul, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath